Immunotherapy and the use of PD-1 and PD-L1 inhibitors have also become an area of interest in the treatment of nonmelanoma skin cancers including advanced BCC, particularly in patients refractory to Hedgehog pathway inhibitors [10, 18]. The gene discussed is CD274; the disease is skin basal cell carcinoma.